Arsanis, Inc. Contracts & Agreements

X4 Pharmaceuticals, Inc. Amended and Restated 2019 Inducement Equity Incentive Plan (Filed With SEC on August 10, 2023)

X4 Pharmaceuticals, Inc. Amended and Restated 2017 Employment Stock Purchase Plan (Filed With SEC on August 10, 2023)

Form of May 2023 Pre-Funded Warrant (Filed With SEC on May 16, 2023)

Securities Purchase Agreement, dated May 15, 2023, by and among X4 Pharmaceuticals, Inc. and the persons party thereto (Filed With SEC on May 16, 2023)

Registration Rights Agreement, dated May 15, 2023, by and among X4 Pharmaceuticals, Inc. and the persons party thereto (Filed With SEC on May 16, 2023)

X4 Pharmaceuticals, Inc. Amended and Restated 2019 Inducement Equity Incentive Plan (Filed With SEC on December 23, 2022)

Underwriting Agreement, dated December 7, 2022, by and among the Company, Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated, and Cantor Fitzgerald & Co (Filed With SEC on December 9, 2022)

Form of Pre-Funded Warrant (Filed With SEC on December 9, 2022)

Form of Class C Warrant (Filed With SEC on December 9, 2022)

Form of Stock Appreciation Right Agreement under the X4 Pharmaceuticals, Inc. Amended and Restated 2017 Equity Incentive Plan (Filed With SEC on November 9, 2022)

Form of Pre-Funded Warrant (Filed With SEC on July 1, 2022)

Form of Warrant (Filed With SEC on July 1, 2022)

Securities Purchase Agreement, dated June 30, 2022, by and among X4 Pharmaceuticals Inc. and the persons party thereto (Filed With SEC on July 1, 2022)

Registration Rights Agreement, dated June 30, 2022, by and among X4 Pharmaceuticals Inc. and the persons party thereto (Filed With SEC on July 1, 2022)

Amendment No. 4 to Amended and Restated Loan and Security Agreement, dated as of June 30, 2022, by and among X4 Pharmaceuticals, Inc., each of its Qualified Subsidiaries... (Filed With SEC on July 1, 2022)

Second Amended and Restated Executive Employment Agreement, dated as of March 7, 2022 by and between the Company and Adam S. Mostafa (Filed With SEC on March 17, 2022)

Amended and Restated Executive Employment Agreement, dated as of March 7, 2022 by and between the Company and Derek Meisner (Filed With SEC on March 17, 2022)

Amended and Restated Executive Employment Agreement, dated as of March 7, 2022 by and between the Company and Art Taveres (Filed With SEC on March 17, 2022)

Amended and Restated Executive Employment Agreement, dated as of March 7, 2022 by and between the Company and Diego Cadavid (Filed With SEC on March 17, 2022)

Amended and Restated Executive Employment Agreement, dated as of March 7, 2022 by and between the Company and Mary DiBiase (Filed With SEC on March 17, 2022)

Form of Pre-Funded (Filed With SEC on March 3, 2022)

Securities Purchase Agreement, dated March 3, 2022, by and among X4 Pharmaceuticals, Inc. and the persons party thereto (Filed With SEC on March 3, 2022)

Registration Rights Agreement, dated March 3, 2022, by and among X4 Pharmaceuticals, Inc. and the persons party thereto (Filed With SEC on March 3, 2022)

Amendment No. 3 to Amended and Restated Loan and Security Agreement, dated as of February 9, 2022, by and among X4 Pharmaceuticals, Inc., each of its Qualified Subsidiaries... (Filed With SEC on February 9, 2022)

Purchase Agreement, dated as of January 14, 2022, by and between X4 Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on January 14, 2022)

Registration Rights Agreement, dated as of January 14, 2022, by and between X4 Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on January 14, 2022)

Form of Pre-Funded Warrant (Filed With SEC on November 5, 2021)

Securities Purchase Agreement, dated November 5, 2021, by and among X4 Pharmaceuticals, Inc. and the persons party thereto (Filed With SEC on November 5, 2021)

Registration Rights Agreement, dated November 5, 2021, by and among X4 Pharmaceuticals, Inc. and the persons party thereto (Filed With SEC on November 5, 2021)

Third Amendment to Option Agreement, dated July 15, 2021, by and between X4 Pharmaceuticals, Inc. and Abingworth Bioventures 8 LP (Filed With SEC on July 15, 2021)

Second Amendment to Option Agreement, dated June 7, 2021, by and between X4 Pharmaceuticals, Inc. and Abingworth Bioventures 8 LP (Filed With SEC on June 7, 2021)

First Amendment to Option Agreement dated May 3, 2021, by and between X4 Pharmaceuticals Inc. and Abingworth Bioventures 8 LP (Filed With SEC on May 6, 2021)

Description of Registered Securities (Filed With SEC on March 19, 2021)

Executive Employment Agreement, dated as of October 21, 2020, by and between the Company and Art Taveres (Filed With SEC on March 19, 2021)

Executive Employment Agreement, dated as of November 23, 2020, by and between the Company and Diego Cadavid (Filed With SEC on March 19, 2021)

License Agreement, dated as of November 13, 2020, by and between X4 Pharmaceuticals Inc. and the Dana Farber Cancer Institute (Filed With SEC on March 19, 2021)

Amendment No. 2 to Master Services Agreement, dated February (Filed With SEC on March 19, 2021)

Form of Pre-Funded Warrant (Filed With SEC on March 19, 2021)

Securities Purchase Agreement, dated March 18, 2021, by and among X4 Pharmaceuticals, Inc. and the persons party thereto (Filed With SEC on March 19, 2021)

Registration Rights Agreement, dated March 18, 2021, by and among X4 Pharmaceuticals, Inc. and the persons party thereto (Filed With SEC on March 19, 2021)

Option Agreement, dated March 18, 2021, by and between X4 Pharmaceuticals, Inc. and Abingworth Bioventures 8 LP (Filed With SEC on March 19, 2021)

Amendment No. 2 to Amended and Restated Loan and Security Agreement, dated as of December 21, 2020, by and among X4 Pharmaceuticals, Inc., each of its Qualified Subsidiaries... (Filed With SEC on December 23, 2020)

Consulting agreement, dated September 17 2020, by and between X4 Pharmaceuticals Inc. and Gary Bridger (Filed With SEC on November 5, 2020)

Lease Termination Agreement, dated July 17, 2020, by and between 955 Massachusetts Avenue MA, LLC and X4 Pharmaceuticals, Inc (Filed With SEC on November 5, 2020)

Registration Rights Agreement, dated October 14, 2020, by and between X4 Pharmaceuticals, Inc. and Aspire Capital Fund, LLC (Filed With SEC on October 16, 2020)

Common Stock Purchase Agreement, dated October 14, 2020, by and between X4 Pharmaceuticals, Inc. and Aspire Capital Fund, LLC (Filed With SEC on October 16, 2020)

Amendment to Amended and Restated Executive Employment Agreement, dated as of March 13, 2019, dated February 13, 2020 by and between the Company and Paula Ragan, Ph.D (Filed With SEC on May 7, 2020)

Resignation Agreement and Release by and between X4 Pharmaceuticals, Inc. and E. Lynne Kelley, M.D., dated March 18, 2020 (Filed With SEC on March 20, 2020)

Amendment No. 1 to Loan and Security Agreement, dated March 13, 2020, by and between X4 Pharmaceuticals, Inc. and Hercules Capital, Inc (Filed With SEC on March 17, 2020)

Description of Registered Securities (Filed With SEC on March 12, 2020)

Executive Employment Agreement, dated as of April 16, 2019, by and between the Company and E. Lynne Kelley (Filed With SEC on March 12, 2020)

Amendment to Amended and Restated Executive Employment Agreement, dated as of March 13, 2019, dated February 13, 2020 by and between the Company and Paula Ragan, Ph.D (Filed With SEC on March 12, 2020)

Amendment to Amended and Restated Executive Employment Agreement, dated as of February 24, 2020 by and between the Company and Adam S. Mostafa (Filed With SEC on March 12, 2020)

Amendment to Executive Employment Agreement, dated as of March 5, 2020, by and between the Company and E. Lynne Kelley (Filed With SEC on March 12, 2020)

Executive Employment Agreement, dated as of September 25, 2019, by and between the Company and Derek Meisner (Filed With SEC on March 12, 2020)

Amendment to Executive Employment Agreement, dated as of February 24, 2020, by and between the Company and Derek Meisner (Filed With SEC on March 12, 2020)

Master Services Agreement, dated September 10, 2015, by and between X4 Pharmaceuticals Inc. and Mayne Pharma Inc. (formerly known as Metrics, Inc.) (Filed With SEC on March 12, 2020)

Amendment No. 1 to Master Services Agreement, dated August 25, 2017, by and between X4 Pharmaceuticals Inc. and Mayne Pharma Inc. (formerly known as Metrics, Inc.) (Filed With SEC on March 12, 2020)

Amendment No. 2 to Master Services Agreement, dated February 28, 2020, by and between X4 Pharmaceuticals Inc. and Mayne Pharma Inc (Filed With SEC on March 12, 2020)

Master Services Agreement, dated February 19, 2016, by and between X4 Pharmaceuticals Inc. and Aptuit (Oxford) Limited (Filed With SEC on March 12, 2020)

Amendment No. 1 to Master Services Agreement, dated February 19, 2016, by and between X4 Pharmaceuticals Inc. and Aptuit (Oxford) Limited (Filed With SEC on March 12, 2020)

Lease, dated as of November 11, 2019, by and between X4 Pharmaceuticals Inc. and Beacon North Village, LLC (Filed With SEC on March 12, 2020)

Underwriting Agreement, dated November 26, 2019, by and among the Company, Cowen and Company, LLC and Stifel, Nicolaus & Company, Incorporated (Filed With SEC on November 27, 2019)

Form of Pre-Funded Warrant (Filed With SEC on November 27, 2019)

Form of Class B Warrant (Filed With SEC on November 27, 2019)

Amended and Restated Loan and Security Agreement, dated as of June 27, 2019, by and among X4 Pharmaceuticals, Inc., X4 Therapeutics, Inc., Hercules Capital, Inc. and Hercules... (Filed With SEC on June 28, 2019)

X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (Filed With SEC on June 19, 2019)

Form of Stock Option Agreement under the 2019 Inducement Equity Incentive Plan (Filed With SEC on June 19, 2019)

Form of Restricted Stock Agreement under the 2019 Inducement Equity Incentive Plan (Filed With SEC on June 19, 2019)

Form of Restricted Stock Unit Agreement under the 2019 Inducement Equity Incentive Plan (Filed With SEC on June 19, 2019)

Form of Restricted Stock Unit Agreement under the Companys 2017 Equity Incentive Plan (Filed With SEC on June 19, 2019)

Form of Restricted Stock Unit Agreement under the Companys 2015 Employee, Director and Consultant Equity Incentive Plan, as amended (Filed With SEC on June 19, 2019)

Amended and Restated Warrant Agreement, dated as of March 29, 2019, by and between the Company and Hercules Capital, Inc (Filed With SEC on May 15, 2019)

Warrant Agreement, dated as of March 18, 2019, by and between the Company and Hercules Capital, Inc (Filed With SEC on May 15, 2019)

Form of Restricted Stock Agreement under the 2017 Equity Incentive Plan (Filed With SEC on May 15, 2019)

Form of Nonstatutory Stock Option Agreement (Director Grants) under the 2017 Equity Incentive Plan (Filed With SEC on May 15, 2019)

Form of Nonstatutory Stock Option Agreement under the 2017 Equity Incentive Plan (Filed With SEC on May 15, 2019)

Form of Incentive Stock Option Agreement under the 2017 Equity Incentive Plan (Filed With SEC on May 15, 2019)

License Agreement, dated as of July 10, 2014, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, LLC) and Genzyme Corp., a Sanofi company (Filed With SEC on May 13, 2019)

Amendment No. 1 to License Agreement, dated as of October 23, 2014, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Genzyme Corporation, a Sanofi... (Filed With SEC on May 13, 2019)

License Agreement, dated as of December 13, 2016, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Georgetown University (Filed With SEC on May 13, 2019)

Exclusive License Agreement, dated as of December 23, 2016, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Beth Israel Deaconess Medical Center (Filed With SEC on May 13, 2019)

Underwriting Agreement, dated April 12, 2019, by and among the Company, Cowen and Company, LLC and Stifel, Nicolaus & Company, Incorporated (Filed With SEC on April 15, 2019)

Form of Pre-Funded Warrant (Filed With SEC on April 15, 2019)

Form of Class A Warrant (Filed With SEC on April 15, 2019)

Settlement Agreement, dated as of March 8, 2019, by and among X4 Pharmaceuticals, Inc. (formerly Arsanis, Inc.), Artemis AC Corp., X4 Therapeutics, Inc. (formerly X4... (Filed With SEC on April 11, 2019)

Form of Stock Option Agreement under the 2015 Employee, Director and Consultant Equity Incentive Plan, as amended (Filed With SEC on April 3, 2019)

Form of Common Stock Certificate (Filed With SEC on March 13, 2019)

Form of Warrant to Purchase Series A Preferred Stock of X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) issued to Silicon Valley Bank and Life Science Loans, LLC (Filed With SEC on March 13, 2019)

Form of Warrant to Purchase Series A Preferred Stock of X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) issued to Maxim Partners LLC (Filed With SEC on March 13, 2019)

Form of Warrant to Purchase Series B Preferred Stock of X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) (Filed With SEC on March 13, 2019)

Form of Warrant to Purchase Series B Preferred Stock of X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) issued to Hercules Capital, Inc (Filed With SEC on March 13, 2019)

Warrant Modification Agreement, dated as of December 11, 2018, by and among X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Hercules Capital, Inc (Filed With SEC on March 13, 2019)

2015 Employee, Director and Consultant Equity Incentive Plan, as amended (Filed With SEC on March 13, 2019)

Form of Stock Option Agreement under the 2015 Employee, Director and Consultant Equity Incentive Plan, as amended (Filed With SEC on March 13, 2019)

Director Compensation Policy (Filed With SEC on March 13, 2019)

Amended and Restated Executive Employment Agreement, dated as of March 13, 2019, by and between the Company and Paula Ragan, Ph.D (Filed With SEC on March 13, 2019)

Amended and Restated Executive Employment Agreement, dated as of March 13, 2019, by and between the Company and Adam S. Mostafa (Filed With SEC on March 13, 2019)

License Agreement, dated as of July 10, 2014, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, LLC) and Genzyme Corp., a Sanofi company (Filed With SEC on March 13, 2019)

Amendment No. 1 to License Agreement, dated as of October 23, 2014, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Genzyme Corporation, a Sanofi... (Filed With SEC on March 13, 2019)

License Agreement, dated as of December 13, 2016, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Georgetown University (Filed With SEC on March 13, 2019)

Exclusive License Agreement, dated as of December 23, 2016, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Beth Israel Deaconess Medical Center (Filed With SEC on March 13, 2019)

Loan and Security Agreement, dated as of October 19, 2018, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Hercules Capital, Inc (Filed With SEC on March 13, 2019)

Amendment No. 1 to Loan and Security Agreement, dated as of December 11, 2018, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Hercules Capital, Inc (Filed With SEC on March 13, 2019)

Lease, dated as of January 20, 2017, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Brickman 955 Massachusetts LLC (Filed With SEC on March 13, 2019)

Second Amendment to Agreement and Plan of Merger, dated March 8, 2019, by and among Arsanis, Inc., Artemis AC Corp. and X4 Pharmaceuticals, Inc (Filed With SEC on March 8, 2019)

Lease Termination Agreement, dated February 26, 2019, by and between Arsanis Biosciences GmbH and Wstenrot Marxbox GmbH & Co. OG (as successor-in-interest to Marxbox Bauprojekt... (Filed With SEC on March 1, 2019)

First Amendment to Agreement and Plan of Merger, dated December 20, 2018, by and among Arsanis, Inc., Artemis AC Corp. and X4 Pharmaceuticals, Inc (Filed With SEC on December 20, 2018)

Agreement and Plan of Merger, dated November 26, 2018, by and among Arsanis, Inc., Artemis AC Corp. and X4 Pharmaceuticals, Inc (Filed With SEC on November 27, 2018)

Form of Support Agreement, dated November 26, 2018, by and among Arsanis, Inc., X4 Pharmaceuticals, Inc. and certain stockholders of Arsanis, Inc (Filed With SEC on November 27, 2018)

Form of Support Agreement, dated November 26, 2018, by and among Arsanis, Inc., X4 Pharmaceuticals, Inc. and certain officers, directors and stockholders of X4 Pharmaceuticals, Inc (Filed With SEC on November 27, 2018)

2018 Amended and Restated Employment Agreement, dated November 26, 2018, by and between Arsanis, Inc. and Michael Gray (Filed With SEC on November 27, 2018)

Letter Agreement, dated November 26, 2018, by and between Arsanis, Inc. and Ren Russo (Filed With SEC on November 27, 2018)

Retention Bonus Agreement, dated November 26, 2018, by and between Arsanis, Inc. and Christopher Stevens (Filed With SEC on November 27, 2018)

Form of Restricted Stock Agreement under the 2017 Equity Incentive Plan (Filed With SEC on November 27, 2018)

First Amendment to Lease, dated August 10, 2018, by and between the Registrant and BP Bay Colony LLC (Filed With SEC on August 13, 2018)

Amended and Restated Agreement, dated August 8, 2018, by and between the Registrant and the Bill & Melinda Gates Foundation (Filed With SEC on August 13, 2018)

Grant Agreement, dated August 8, 2018, by and between the Registrant and the Bill & Melinda Gates Foundation (Filed With SEC on August 13, 2018)

Forbearance Agreement, dated August 8, 2018, by and between the Registrant and Silicon Valley Bank (Filed With SEC on August 13, 2018)

Indenture of Lease, dated June 6 2018, by and between the Company and BP Bay Colony LLC (Filed With SEC on June 12, 2018)

Share Purchase Agreement, dated as of November 15, 2017, by and between the Company and New Enterprise Associates 16, L.P (Filed With SEC on March 9, 2018)

Arsanis, Inc. [] Shares Common Stock ($0.001 parvalue) Underwriting Agreement (Filed With SEC on November 6, 2017)

ARSANIS, INC. SECONDAMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT Dated as of April 12, 2016 Amended as of November 3, 2017 (Filed With SEC on November 6, 2017)

INDEMNIFICATION AGREEMENT (Filed With SEC on November 6, 2017)

ARSANIS, INC. SECONDAMENDED AND RESTATED STOCKHOLDERS AGREEMENT Dated as of April 12, 2016 Amended as of November 3, 2017 TABLE OF CONTENTS (Filed With SEC on November 6, 2017)

Specimen Stock Certificate evidencing the shares of common stock (Filed With SEC on October 20, 2017)

Second Amended and Restated Investors Rights Agreement, as amended (Filed With SEC on October 20, 2017)

2010 Special Stock Incentive Plan, as amended (Filed With SEC on October 20, 2017)

Form of Non-Statutory Stock Option Agreement under the 2010 Special Stock Incentive Plan (Filed With SEC on October 20, 2017)

2011 Stock Incentive Plan, as amended (Filed With SEC on October 20, 2017)

Form of Incentive Stock Option Agreement under the 2011 Stock Incentive Plan (Filed With SEC on October 20, 2017)

Form of Non-Statutory Stock Option Agreement under the 2011 Stock Incentive Plan (Filed With SEC on October 20, 2017)

2017 Equity Incentive Plan (Filed With SEC on October 20, 2017)

Form of Incentive Stock Option Agreement under the 2017 Equity Incentive Plan (Filed With SEC on October 20, 2017)

Form of Nonstatutory Stock Option Agreement under the 2017 Equity Incentive Plan (Filed With SEC on October 20, 2017)

2017 Employee Stock Purchase Plan (Filed With SEC on October 20, 2017)

Offer letter, dated July 12, 2015, by and between the Registrant and Ren Russo (Filed With SEC on October 20, 2017)

Offer letter, dated January 15, 2016, by and between the Registrant and Michael Gray (Filed With SEC on October 20, 2017)

Offer letter, dated April 28, 2016, by and between the Registrant and Chris Stevens (Filed With SEC on October 20, 2017)

Form of Indemnification Agreement between Registrant and each of William Clark, Carl Gordon, David McGirr, Terrance McGuire, Claudio Nessi, Michael Ross and Amy Schulman (Filed With SEC on October 20, 2017)

Form of Indemnification Agreement between Registrant and each of Eszter Nagy, Tillman U. Gerngross and Rene Russo (Filed With SEC on October 20, 2017)

Lease, dated October 30, 2015, by and between the Registrant and Waltham Winter Street 890 LP and the Registrant (Filed With SEC on October 20, 2017)

Lease Agreement, dated November 26, 2010, by and between Arsanis Biosciences GmbH and Wstenrot Marxbox GmbH & Co. OG (as successor-in-interest to Marxbox Bauprojekt GmbH & Co.... (Filed With SEC on October 20, 2017)

Collaboration Agreement, dated as of May 1, 2011, by and between the Registrant and Adimab, LLC, as amended (Filed With SEC on October 20, 2017)

Option and License Agreement, dated as of February 27, 2017, by and between the Registrant and Adimab, LLC (Filed With SEC on October 20, 2017)

Grant Agreement, dated February 20, 2017, by and between the Registrant and Bill & Melinda Gates Foundation, as amended (Filed With SEC on October 20, 2017)

Letter agreement, dated as of April 24, 2017, by and between the Registrant and Bill & Melinda Gates Foundation (Filed With SEC on October 20, 2017)

Loan and Security Agreement, dated as of December 7, 2012, by and between the Registrant and Silicon Valley Bank, as amended (Filed With SEC on October 20, 2017)

Warrant to purchase shares of Series A-2 Convertible Preferred Stock issued by the Registrant to Silicon Valley Bank (Filed With SEC on October 20, 2017)

Warrant to purchase shares of Series B Convertible Preferred Stock issued by the Registrant to Silicon Valley Bank (Filed With SEC on October 20, 2017)

Funding contract, dated September 20, 2011, by and between Arsanis Biosciences GmbH and sterreichische Forschungsfrderungsgesellschaft mbH (English translation) (Filed With SEC on October 20, 2017)

Funding contract, dated July 2, 2012, by and between Arsanis Biosciences GmbH and sterreichische Forschungsfrderungsgesellschaft mbH (English translation) (Filed With SEC on October 20, 2017)

Funding contract, dated December 5, 2012, by and between Arsanis Biosciences GmbH and sterreichische Forschungsfrderungsgesellschaft mbH (English translation) (Filed With SEC on October 20, 2017)

Funding contract, dated March 29, 2013, by and between Arsanis Biosciences GmbH and sterreichische Forschungsfrderungsgesellschaft mbH (English translation) (Filed With SEC on October 20, 2017)

Funding contract, dated August 6, 2013, by and between Arsanis Biosciences GmbH and sterreichische Forschungsfrderungsgesellschaft mbH (English translation) (Filed With SEC on October 20, 2017)

Funding contract, dated April 3, 2014, by and between Arsanis Biosciences GmbH and sterreichische Forschungsfrderungsgesellschaft mbH (English translation) (Filed With SEC on October 20, 2017)

Funding contract, dated June 9, 2014, by and between Arsanis Biosciences GmbH and sterreichische Forschungsfrderungsgesellschaft mbH (English translation) (Filed With SEC on October 20, 2017)

Funding contract, dated July 20, 2015, by and between Arsanis Biosciences GmbH and sterreichische Forschungsfrderungsgesellschaft mbH (English translation) (Filed With SEC on October 20, 2017)

Funding contract, dated July 14, 2016, by and between Arsanis Biosciences GmbH and sterreichische Forschungsfrderungsgesellschaft mbH (English translation) (Filed With SEC on October 20, 2017)

Funding contract, dated March 23, 2017, by and between Arsanis Biosciences GmbH and sterreichische Forschungsfrderungsgesellschaft mbH (English translation) (Filed With SEC on October 20, 2017)

Form of Indemnification Agreement to be entered into between the Registrant and each of its directors and executive officers (Filed With SEC on October 20, 2017)

Second Amended and Restated Stockholders Agreement, dated as of April 12, 2016, among the Registrant and the other parties thereto, as amended (Filed With SEC on October 20, 2017)

Amended and Restated Offer Letter, dated October 10, 2017, by and between the Registrant and Ren Russo (to be effective upon the closing of this offering) (Filed With SEC on October 20, 2017)

Amended and Restated Offer Letter, dated October 10, 2017, by and between the Registrant and Michael Gray (to be effective upon the closing of this offering) (Filed With SEC on October 20, 2017)

Amended and Restated Offer Letter, dated October 10, 2017, by and between the Registrant and Chris Stevens (to be effective upon the closing of this offering) (Filed With SEC on October 20, 2017)

Amendment No. 1 to the Option and License Agreement, dated as of February 27, 2017, by and between the Registrant and Adimab, LLC, dated as of October 13, 2017 (Filed With SEC on October 20, 2017)